CSIMarket Company Name, Ticker, Suppliers, else..
 
Cabaletta Bio Inc   (NASDAQ: CABA)
 

Cabaletta Bio Inc's Suppliers Performance

CABA's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
CABA Costs vs Sales of Suppliers Growth

• More on CABA Suppliers






Cabaletta Bio Inc's Comment on Supply Chain


Since 2023, the company has partnered with Cellares Corporation to implement automated manufacturing for rese-cel, enabling scalable production with reduced capital investment and flexible scheduling. Cellares is currently producing rese-cel for the RESET TM clinical program, with initial clinical experience expected in the first half of 2026 and full clinical and durability data anticipated in the second half of 2026. The company is also developing innovations for rese-cel, including a no preconditioning approach, which has demonstrated promising early clinical responses in trials such as RESET-PV and RESET-SLE. The company aims to optimize patient experience and scale manufacturing to address autoimmune diseases with targeted cellular therapies.

Cabaletta Bio Inc's Comment on Supply Chain


Since 2023, the company has partnered with Cellares Corporation to implement automated manufacturing for rese-cel, enabling scalable production with reduced capital investment and flexible scheduling. Cellares is currently producing rese-cel for the RESET TM clinical program, with initial clinical experience expected in the first half of 2026 and full clinical and durability data anticipated in the second half of 2026. The company is also developing innovations for rese-cel, including a no preconditioning approach, which has demonstrated promising early clinical responses in trials such as RESET-PV and RESET-SLE. The company aims to optimize patient experience and scale manufacturing to address autoimmune diseases with targeted cellular therapies.







CABA's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Cabaletta Bio Inc 385.46 0.00 -181.32 156
SUBTOTAL 0.00 0.00 0.00 -


Sources: Cabaletta Bio Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Cabaletta Bio Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.